Table. 2 Logistic regression of H2AFY expression and clinical characteristics
From: The diagnostic and prognostic value of H2AFY in hepatocellular carcinoma
Clinical characteristic | Total (N) | Odds ratio of H2AFY expression | 95%CI | p-value |
|---|---|---|---|---|
Age (>61vs ≤ 61) | 376 | 0.57 | 0.37–0.86 | 0.007 |
Clinical stage (Stage III vs Stage I) | 256 | 1.78 | 1.05–3.03 | 0.030 |
G stage | ||||
 (G2 vs G1) | 235 | 1.96 | 1.02–3.90 | 0.048 |
 (G3 vs G1) | 179 | 5.53 | 2.77–11.49 | 2.0857e-06 |
 (G4 vs G1) | 68 | 5.20 | 1.42–21.97 | 0.015 |
T stage (T4 vs T1) | 198 | 4.30 | 1.26–19.66 | 0.030 |
N stage (N1 vs N0) | 261 | 3.04 | 0.38–62.07 | 0.337 |
M stage (M1 vs M0) | 271 | 3.04 | 0.38–61.99 | 0.337 |
Sex (Male vs Female) | 377 | 0.83 | 0.54–1.28 | 0.417 |